OKTA vs STRO · P/E 84, rev $2.61B vs rev $62.0M
Okta Inc (OKTA) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported OKTA revenue for 2025-01-31 was $2.61B. Net income was $28.0M. Revenue was up 15.3% from 2024-01-31 to 2025-01-31. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
OKTA currently screens at market cap $20.06B and trailing P/E 83.6. STRO currently screens at market cap $470.8M.
Not investment advice. Open the OKTA and STRO stock pages for the full models.
Not investment advice.